ArticleInternational journal of molecular sciences2018
Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Effect of (Poly)phenols on Lipid and Glucose Metabolisms in 3T3-L1 Adipocytes: an Integrated Analysis of Mechanistic Approaches.Current obesity reports · 2025Pooled it
- Metabolic Syndrome in an Aging Society - Role of Oxidant-Antioxidant Imbalance and Inflammation Markers in Disentangling Atherosclerosis.Clinical interventions in aging · 2021Pooled it
- Review
- Synergistic Effects of Bioactive Compounds on Human Adiposity Mechanisms of Fat Loss and Fat Accumulation.Food science & nutrition · 2025Review
- Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway.Scientific reports · 2025Article
- A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes.Drug design, development and therapy · 2025Review
- Phytochemical Composition ofAdvances in pharmacological and pharmaceutical sciences · 2025Review
- Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease.Theranostics · 2024Article
- The role of anti-aging approaches in managing hypogonadism in sedentary older males.Frontiers in aging · 2024Review
- Ginsenoside Rg3 Protects against Diabetic Cardiomyopathy and Promotes Adiponectin Signaling via Activation of PPAR-γ.International journal of molecular sciences · 2023Article
- Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism.Frontiers in pharmacology · 2023Review
- Sirtfoods: New Concept Foods, Functions, and Mechanisms.Foods (Basel, Switzerland) · 2022Review
- Neuroprotective Effects of Resveratrol by Modifying Cholesterol Metabolism and Aβ Processing in SAMP8 Mice.International journal of molecular sciences · 2022Article
- The Effects of Antioxidants from Natural Products on Obesity, Dyslipidemia, Diabetes and Their Molecular Signaling Mechanism.International journal of molecular sciences · 2022Review
- Ginsenoside Rb1 Protects Against Diabetic Cardiomyopathy by Regulating the Adipocytokine Pathway.Journal of inflammation research · 2022Article
- Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.Pharmaceutical research · 2021Article
- Berberine Inhibits Dengue Virus through Dual Mechanisms.Molecules (Basel, Switzerland) · 2021Article
- Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction.International journal of molecular sciences · 2021Review
- Aberrant ROS Mediate Cell Cycle and Motility in Colorectal Cancer Cells Through an Oncogenic CXCL14 Signaling Pathway.Frontiers in pharmacology · 2021Article
- Autologous erythrocytes delivery of berberine hydrochloride with long-acting effect for hypolipidemia treatment.Drug delivery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The natural compound berberine has been reported to exhibit anti-diabetic activity and to improve disordered lipid metabolism. In our previous study, we found that such compounds upregulate expression of sirtuin 1-a key molecule in caloric restriction, it is, therefore, of great interest to examine the lipid-lowering activity of berberine in combination with a sirtuin 1 activator resveratrol. Our results showed that combination of berberine with resveratrol had enhanced hypolipidemic effects in high fat diet-induced mice and was able to decrease the lipid accumulation in adipocytes to a level significantly lower than that in monotherapies. In the high fat diet-induced hyperlipidemic mice, combination of berberine (30 mg/kg/day, oral) with resveratrol (20 mg/kg/day, oral) reduced serum total cholesterol by 27.4% ± 2.2%, and low-density lipoprotein-cholesterol by 31.6% ± 3.2%, which was more effective than that of the resveratrol (8.4% ± 2.3%, 6.6% ± 2.1%) or berberine (10.5% ± 1.95%, 9.8% ± 2.58%) monotherapy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.